Search by Drug Name or NDC
NDC 80725-0630-25 TABLOID 40 mg/1 Details
TABLOID 40 mg/1
TABLOID is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Waylis Therapeutics LLC. The primary component is THIOGUANINE.
MedlinePlus Drug Summary
Thioguanine is used to treat acute myeloid leukemia (AML; a type of cancer that begins in the white blood cells). Thioguanine is in a class of medications known as purine analogs. It works by slowing or stopping the growth of cancer cells in your body.
Related Packages: 80725-0630-25Last Updated: 05/26/2024
MedLinePlus Full Drug Details: Thioguanine
Product Information
| NDC | 80725-0630 |
|---|---|
| Product ID | 80725-630_4f31c81f-0c6e-4c3f-9f50-44578fad9988 |
| Associated GPIs | |
| GCN Sequence Number | 008808 |
| GCN Sequence Number Description | thioguanine TABLET 40 MG ORAL |
| HIC3 | V1B |
| HIC3 Description | ANTINEOPLASTIC - ANTIMETABOLITES |
| GCN | 10290 |
| HICL Sequence Number | 003911 |
| HICL Sequence Number Description | THIOGUANINE |
| Brand/Generic | Brand |
| Proprietary Name | TABLOID |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | thioguanine |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 40 |
| Active Ingredient Units | mg/1 |
| Substance Name | THIOGUANINE |
| Labeler Name | Waylis Therapeutics LLC |
| Pharmaceutical Class | Antimetabolite [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA012429 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 80725-0630-25 (80725063025)
| NDC Package Code | 80725-630-25 |
|---|---|
| Billing NDC | 80725063025 |
| Package | 1 BOTTLE in 1 CARTON (80725-630-25) / 25 TABLET in 1 BOTTLE |
| Marketing Start Date | 2023-05-15 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |